{"schema_version":"secwatch.filing_event.v1","accession":"0001490978-25-000116","form_type":"8-K","ticker":"SDGR","cik":"0001490978","company_name":"Schrodinger, Inc.","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.517694+00:00","generated_at":"2026-05-17T00:15:14.536006+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Schrödinger Q3 revenue up 54% to $54.3M; software growth 28%, FY guidance trimmed","bullets":["Total revenue $54.3M (+54% YoY); software revenue $40.9M (+28%); drug discovery $13.5M.","GAAP net loss narrowed to $32.8M from $38.1M; non-GAAP net loss $42.3M (was $63.7M).","FY2025 software revenue growth guidance cut to 8-13% (from 10-15%); drug discovery raised to $49-52M.","Shift to discovery-focused R&D; not advancing programs independently, expects ~$70M savings.","SGR-1505 got Orphan Drug Designation; SGR-6016 selected as development candidate."],"urls":{"canonical":"https://secwatch.observer/filing/0001490978-25-000116","json":"https://secwatch.observer/filing/0001490978-25-000116.json","markdown":"https://secwatch.observer/filing/0001490978-25-000116.md","text":"https://secwatch.observer/filing/0001490978-25-000116.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1490978/000149097825000116/0001490978-25-000116-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1490978/000149097825000116/sdgr-20251105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:15:14.536006+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}